Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler
DrugParticipants will be prescribed both long-acting and short-acting nicotine replacement therapy.
NCT Number: NCT04490057
Many people living with HIV (PLWH) smoke. Smoking in these individuals is often undertreated. This study plans to assess the ability of various clinical pathways involving tobacco treatment medications and contingency management (paying smokers for not smoking) to improve smoking cessation in a group of PLWH.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Bridgeport Hospital Infectious Disease Clinic, Bridgeport, Connecticut, United States
Using a Sequential Multiple Assignment Randomized Trial (SMART) design, this project is a two-arm, two-stage randomized trial of 320 adult PWH who smoke cigarettes and receive care in one of three health systems (targeted enrollment changed from 632 to 320 with NCI approval and IRB protocol amendment). At inception, participants will be randomized to either combination nicotine replacement therapy (NRT, patch + short-acting NRT) or combination NRT+contingency management (CM). At 12 weeks, responders (non-smoking participants confirmed by exhaled carbon monoxide [eCO] or collateral verification) in both arms will receive 12 more weeks of the same treatment. Non-responders (participants with continued smoking by self-report and/or eCO) in both the NRT and NRT+CM arms will be re-randomized to 12 weeks of treatment, either with medication switch to oral medication, varenicline or bupropion, or intensified level of CM (start CM if no CM during first 12 weeks, or CM with higher reward schedule ["CM plus"] if NRT+CM group initially). The intervention will be delivered by trained clinical pharmacists. The primary outcomes will be self-reported reduction in average cigarettes smoked per day at 24 weeks and 12 weeks (primary outcome changed from eCO-confirmed abstinence to self-reported abstinence with NCI approval and IRB protocol amendment). The specific aims of the proposed study are to: (1) identify the optimal adaptive approach to promote reduced tobacco use (changed from eCO-confirmed smoking abstinence with NCI approval and protocol amendment) (2) study the effectiveness of various adaptive strategies on CD4 count, HIV viral suppression, and VACS index (validated measure of morbidity and mortality risk); and (3) grounded in implementation science and using aHybrid Effectiveness-Implementation Type I design, identify barriers and facilitators to delivering our intervention to inform future implementation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.
Participants will be prescribed varenicline (Chantix) or bupropion (Wellbutrin).
Participants will be financially rewarded for abstinence to tobacco.
Time frame: Week 12
Self reported reduction in average cigarettes smoked per day at 12 weeks
Time frame: 24 weeks
Self reported reduction in cigarettes smoked per day at 24 weeks
Time frame: 12 weeks from baseline
Number of participants with smoking abstinence confirmed by exhaled carbon monoxide or next closest informant verification
Time frame: 24 weeks from baseline
Number of participants with smoking abstinence confirmed by exhaled carbon monoxide or next closest informant verification
Time frame: 24 weeks from baseline
The Veterans Aging Cohort Study (VACS) 2.0 Index is A validated measure of morbidity and mortality. It estimates risk of 5-year all-cause mortality in patients with HIV. Total score range of 0-129. A higher total score indicates a greater risk of adverse health outcomes.
Time frame: 24 weeks from baseline
CD4 lymphocyte cell count. Normal range is 500-1200 cells per cubic millimeter. As HIV infection progresses, CD4 count drops.
Time frame: 24 weeks from baseline
HIV viral load greater than 200 copies per milliliter of blood and detectable on standard lab test
Yale University
Other
Acronym: SMARTTT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06629467
Behavior, Health Behavior
Oviedo, Principality of Asturias, Spain
View Trial DetailsNCT06458205
Behavior, Health Behavior
Zunyi, Guizhou, China
View Trial DetailsNCT05396911
Behavior, Electronic Cigarette Use
Charlottesville, Virginia, United States
View Trial DetailsNCT05952401
Behavior, Chemically-Induced Disorders
St Louis, Missouri, United States
View Trial Details